Dynepo Infrequent Dosing Study

Inclusion Criteria: * Aged at least 18 years with chronic kidney disease (Kidney Disease Outcomes Quality Initiative \[KDOQI\] stage III-V). * Stable on and taking doses \<= 10,000 IU/week of subcutaneous (sc) EPO or requiring initiation of EPO. * Transferrin saturation \>= 20% and ferritin \>= 100 ng/mL. Exclusion Criteria: * Uncontrolled hypertension. * Requiring doses of EPO \> 10,000 IU/week. * Two or more doses of prescribed EPO treatment missed ot withheld by physician order in the 14 days immediately prior tp randomisation in the study. * Active bleeding disorder (diathesis) (for example, Gastrointestinal or Genitourinary tract bleeding). * Treatment with immunosuppressive drugs (other than corticosteroids for a chronic condition) in the 30 days immediately prior to randomisation in the study. * Androgen therapy in the 30 days immediately prior to randomisation in the study. * Known Human Immunodeficiency Virus(HIV)infection. * History of hypersensitivity to EPO therapy or to any of the excipients of Dynepo.